APA (7th ed.) Citation

C, H., LM, M., H, K., HB, B., T, T., WS, W., . . . E, R. (2023). ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma. Frontiers in immunology, 14, 1228894. https://doi.org/10.3389/fimmu.2023.1228894

Chicago Style (17th ed.) Citation

C, Heim, et al. "ErbB2 (HER2)-CAR-NK-92 Cells for Enhanced Immunotherapy of Metastatic Fusion-driven Alveolar Rhabdomyosarcoma." Frontiers in Immunology 14 (2023): 1228894. https://doi.org/10.3389/fimmu.2023.1228894.

MLA (9th ed.) Citation

C, Heim, et al. "ErbB2 (HER2)-CAR-NK-92 Cells for Enhanced Immunotherapy of Metastatic Fusion-driven Alveolar Rhabdomyosarcoma." Frontiers in Immunology, vol. 14, 2023, p. 1228894, https://doi.org/10.3389/fimmu.2023.1228894.